vepdegestrant

News

ASCO 25: AZ pitches upfront oral SERD use in breast cancer

AstraZeneca stakes a claim to first-line treatment of HR+ breast cancer with its oral SERD, as Arvinas/Pfizer reveal their second-line data.

News

Pfizer's new drug data in breast cancer draws muted response

Pfizer and Arvinas' much-anticipated oral SERD vepdegestrant for breast cancer missed a key endpoint in its first phase 3 readout.

News

Data cues up AZ oral SERD filing in first-line breast cancer

AstraZeneca could be the first to bring an oral SERD to market in first-line breast cancer after camizestrant hit the mark in a phase 3 trial.

News

11 blockbuster drugs to look out for in 2025

Clarivate has revealed 11 drugs due to launch in 2025 that could top $1 billion in annual sales or be clinical 'game changers' in the next five years.

ASCO 25: AZ pitches upfront oral SERD use in breast cancer

Pfizer's new drug data in breast cancer draws muted response

Data cues up AZ oral SERD filing in first-line breast cancer

11 blockbuster drugs to look out for in 2025

Parexel buys Vitrana to boost patient safety toolkit

Discover a new era of healthcare panel engagement: Grounded ...

vepdegestrant

Editor's Picks